共 157 条
[1]
Visser K(2009)Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative Ann Rheum Dis 68 1086-93
[2]
Katchamart W(2012)2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res (Hoboken) 64 625-39
[3]
Loza E(2014)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann Rheum Dis 73 492-509
[4]
Martinez-Lopez JA(2005)Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities Ann Rheum Dis 64 207-11
[5]
Salliot C(2014)Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort Clin Rheumatol 33 609-14
[6]
Trudeau J(2009)Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research Ann Rheum Dis 68 1100-4
[7]
Bombardier C(2013)Drug exposure limitations of oral methotrexate (MTX) at doses > 15mgs may be overcome by using a subcutaneous MTX auto-injector in patients with rheumatoid arthritis (RA) Arthritis Rheum 65 S337-8
[8]
Carmona L(2014)Subcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexate Clin Exp Rheumatol 32 563-71
[9]
van der Heijde D(2014)New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis Expert Rev Med Devices 11 447-55
[10]
Bijlsma JW(2014)Nearly pain-free self-administration of subcutaneous methotrexate with an autoinjector: results of a phase 2 clinical trial in patients with rheumatoid arthritis who have functional limitations J Clin Rheumatol 20 256-60